Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.

about

Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.

Item

http://www.wikidata.org/entity/Q47139812

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Pazopanib monotherapy in the t ...... le-center retrospective study.

@en

Pazopanib monotherapy in the t ...... le-center retrospective study.

@nl

type

Item

label

Pazopanib monotherapy in the t ...... le-center retrospective study.

@en

Pazopanib monotherapy in the t ...... le-center retrospective study.

@nl

prefLabel

Pazopanib monotherapy in the t ...... le-center retrospective study.

@en

Pazopanib monotherapy in the t ...... le-center retrospective study.

@nl

P1476

Pazopanib monotherapy in the t ...... le-center retrospective study.

@en

P2093

Hyun Jun Kim

http://www.w3.org/2001/XMLSchema#string

Jeeyun Lee

http://www.w3.org/2001/XMLSchema#string

Se Hoon Park

http://www.w3.org/2001/XMLSchema#string

Su Jin Lee

http://www.w3.org/2001/XMLSchema#string

Youjin Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Current and future options in the management and treatment of uterine sarcoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Cediranib for metastatic alveolar soft part sarcoma

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3802/JGO.2018.29.E3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29185261

http://www.w3.org/2001/XMLSchema#string

P932

5709529

http://www.w3.org/2001/XMLSchema#string